Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion of Akari’s ADC ...
New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 spliceosome payload and a novel antibody construct to address one of oncology’s most challenging and valuable solid tumor targets, ...
ADC Therapeutics (NYSE:ADCT) outlined a 2025 strategy centered on expanding ZYNLONTA while significantly reducing costs, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results